Friday, March 29, 2024
News

DCGI likely to approve phase 3 trial data of Covaxin on Tuesday

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

By Shalini Bhardwaj

New Delhi | June 22, 2021 7:14:56 PM IST
The Drugs Controller General of India (DCGI) is likely to approve Phase III trial data of Covaxin on Tuesday, sources said.

The Subject Expert Committee (SEC) under the drug regulator reviewed Covaxin's Phase III trial data on Tuesday and the vaccine's efficacy has turned out to be 77.8 per cent.

Covaxin is an indigenous COVID-19 vaccine produced by Bharat Biotech.

The Hyderabad-based company had submitted data from the Phase III clinical trials of Covaxin to DCGI over the weekend.

The sources said that Bharat Biotech's 'pre-submission' meeting with the World Health Organization (WHO) will take place on Wednesday for approval for Covaxin.

Covaxin is one of the three COVID-19 vaccines which have been given authorisation in the country for vaccination against COVID-19.

The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR). (ANI)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Telangana: Fire breaks out at dump yard ...
'My father was being given slow poison; ...
Uttar Pradesh: Security tightened in Ali...
'Three parties have allied directly...':...
Eknath Shinde's Shiv Sena releases first...
Jailed gangster-turned-politician Mukhta...
More...    
 
 Top Stories
EAM Jaishankar shares glimpse from ... 
"My father was being given slow poi... 
South Africa's former President Jac... 
Pakistan Tehreek-e-Insaf to hold ra... 
Uttar Pradesh: Security tightened i... 
Miami Open: Bopanna-Ebden storms in... 
Anju Bobby questions IOA's decision... 
"Three parties have allied directly...